Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/30418
Title: | Managing multiple myeloma in the elderly: Are we making progress?. | Authors: | Spencer A.;Quach H.;Prince H.M. | Institution: | (Quach, Prince, Spencer) Department of Clinical Hematology, Faculty of Medicine, Nursing and Health Sciences, Monash University, VIC, Australia (Quach) Department of Hematology, Monash Medical Centre, 246 Clayton Road, Clayton, VIC, Australia (Quach, Spencer) Malignant Hematology and Stem Cell Transplantation, Alfred Health-Southern Health Hematology Consortium, VIC, Australia (Quach, Prince) Department of Medicine, University of Melbourne, VIC, Australia (Prince) Hematology Service, Peter MacCallum Cancer Centre, VIC, Australia | Issue Date: | 6-Oct-2012 | Copyright year: | 2011 | Publisher: | Expert Reviews Ltd. (2 Albert Place, London N3 1QB, United Kingdom) | Place of publication: | United Kingdom | Publication information: | Expert Review of Hematology. 4 (3) (pp 301-315), 2011. Date of Publication: June 2011. | Abstract: | Treatment of multiple myeloma has evolved rapidly over the last decade due to novel therapeutic agents. Improved upfront and salvage options have resulted in enhanced survival; however, this has been less pronounced in elderly patients compared with their younger counterparts. Indeed, treatment-related toxicities in older patients may have subverted the survival benefit made by newer treatment modalities. However, owing to the immaturity of current published data, the true survival impact made by novel agents in the elderly patient subgroup is far from being fully appreciated. Improved responses, along with increased salvage options, imply that progress for elderly patients is being made. The current challenge to improve survival for elderly patients not only rests with continued research into tolerable novel treatment regimens, but also, scrupulous supportive care and the judicious use of current novel agents in appropriate dosing, combinations and sequence. Here, we review the outcomes of elderly patients with multiple myeloma over recent years and focus on the current treatment options available for this group. © 2011 Expert Reviews Ltd. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1586/ehm.11.18 | PubMed URL: | 21668395 [http://www.ncbi.nlm.nih.gov/pubmed/?term=21668395] | ISSN: | 1747-4086 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/30418 | Type: | Review | Subjects: | dexamethasone/dt [Drug Therapy] dexamethasone/po [Oral Drug Administration] lenalidomide/cb [Drug Combination] lenalidomide/dt [Drug Therapy] lenalidomide/po [Oral Drug Administration] melphalan/cb [Drug Combination] melphalan/dt [Drug Therapy] melphalan/po [Oral Drug Administration] prednisone/cb [Drug Combination] prednisone/dt [Drug Therapy] thalidomide/cb [Drug Combination] thalidomide/dt [Drug Therapy] thalidomide/po [Oral Drug Administration] maintenance therapy aged cancer combination chemotherapy cancer survival elderly care human multiple cycle treatment multiple myeloma/dt [Drug Therapy] *multiple myeloma/dt [Drug Therapy] priority journal review salvage therapy bortezomib/cb [Drug Combination] bortezomib/dt [Drug Therapy] bortezomib/iv [Intravenous Drug Administration] dexamethasone/cb [Drug Combination] cancer survival cancer combination chemotherapy maintenance therapy aged multiple cycle treatment multiple myeloma / drug therapy *multiple myeloma / *drug therapy priority journal review salvage therapy human elderly care |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.